Version for print Main / Articles / Perimenopausal disorders in women after COVID-19

Perimenopausal disorders in women after COVID-19

Scopus

Abstract

DOI: 10.32364/2618-8430-2024-7-2-4

S.U. Irgasheva, N.S. Nadirkhanova, N.O. Azamkulova

Republican Specialized Scientific and Practical Medical Center for Maternal and Child Health, Tashkent, Uzbekistan

Aim: to assess the health-related quality of life (HRQOL) of women with perimenopause after COVID-19 and to determine the possibilities of hormone replacement therapy (HRT) in the postcovid period.

Patients and Methods: 96 female patients aged 45 to 54 years were examined. Group 1 consisted of 52 female patients who were being treated in a hospital for COVID-19 12–16 weeks before study. Group 2 (comparison group) consisted of 44 female patients without COVID-19. Further, HRT was performed in 21 female patients of group 1 without contraindications (subgroup 1A). HRT regimen: estradiol hemihydrate, 1.58 mg, transdermally sequestered and dydrogesterone, 10 mg, per os. In subgroup 1B, 31 female patients did not undergo HRT. All patients were examined, which included the following: survey, follow-up, hormone blood test and hemostasiogram. HRT efficacy was evaluated after 3 months.

Results: group 1 had more significant neurovegetative, psychoemotional and metabolic disorders, as well as an increase in the frequency of menstrual disorders versus group 2. In group 1, 43/52 (82,7%) of the respondents experienced hot flashes, where 23/52 (44,2%) of female patients noted the first occurrence of hot flashes after suffering COVID-19. In group 2, 16/44 (36,3%) of patients were concerned about this symptom. In group 1, 42.3% (22/52) of patients reported menstrual disorders. In patients of subgroup 1A, the severity of neurovegetative, metabolic and psychoemotional disorders decreased after HRT versus those in subgroup 1B.

Conclusion: in female patients who suffered moderate to severe COVID-19, perimenopausal disorders include more significant neurovegetative, psychoemotional and metabolic symptoms. Cyclic HRT using transdermal estrogens significantly improves the life quality of women, however, the unfavorable comorbid background observed may reduce the effect of hormone therapy.

Keywords: perimenopause, menopausal syndrome, COVID-19, postcovid syndrome, modified Kuperman Index, hormone replacement therapy.

For citation: Irgasheva S.U., Nadirkhanova N.S., Azamkulova N.O. Perimenopausal disorders in women after COVID-19. Russian Journal of Woman and Child Health. 2024;7(2):110–115 (in Russ.). DOI: 10.32364/2618-8430-2024-7-2-4.

ABOUT THE AUTHORS:

Sevara U. Irgasheva — Dr. Sc. (Med.), Leading Specialist of the Educational Department, Republican Specialized Scientific and Practical Medical Center for Maternal and Child Health; 132, M. Ulugbek str., Tashkent, 100124, Uzbekistan; ORCID iD 0000-0002-4290-6447.

Natalia S. Nadirkhanova — Dr. Sc. (Med.), Director of the Republican Specialized Scientific and Practical Medical Center for Maternal and Child Health; 132, M. Ulugbek str., Tashkent, 100124, Uzbekistan; ORCID iD 0000-0002-2270-1960.

Nozima O. Azamkulova — C. Sc. (Med.), Republican Specialized Scientific and Practical Medical Center for Maternal and Child Health; 132, M. Ulugbek str., Tashkent, 100124, Uzbekistan; ORCID iD 0000-0003-3558-0829.

Contact information: Nozima O. Azamkulova, e-mail: doctor.azamkulova@mail.ru.

Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.

There is no conflict of interest.

Received 31.01.2024.

Revised 26.02.2024.

Accepted 22.03.2024.

References

1. Kabi A., Mohanty A., Mohanty A.P., Kumar S. Post COVID-19 Syndrome: A Literature Review. Journal of Advances in Medicine and Medical Research. 2020;31(24):289–295. DOI: 10.9734/jammr/2020/v32i2430781. 2. NICE. COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19. (Electronic resource.) URL: https://www.nice.org.uk/guidance/NG188 (access date: 02.04.2024). 3. Garg R., Agrawal P., Gautam A. et al. COVID-19 Outcomes in Postmenopausal and Perimenopausal Females: Is Estrogen Hormone Attributing to Gender Differences? J Midlife Health. 2020;11(4):250–256. DOI: 10.4103/jmh.jmh_287_20. 4. Якушевская О.В., Юренева С.В. Менопаузальная гормональная терапия в условиях пандемии коронавирусной инфекции COVID-19. Доктор.Ру. 2021;20(1):78–83. DOI: 10.31550/1727-2378-2021-20-1-78-83.Yakushevskaya O.V., Yureneva S.V. Menopausal Hormonal Therapy During COVID-19 Pandemic. Doctor.Ru. 2021;20(1):78–83 (in Russ.). DOI: 10.31550/1727-2378-2021-20-1-78-83. 5. Gjelsvik B., Rosvold E.O., Straand J. et al. Symptom prevalence during menopause and factors associated with symptoms and menopausal age. Results from the Norwegian Hordaland Women's Cohort study. Maturitas. 2011;70(4):383–390. DOI: 10.1016/j.maturitas.2011.09.011. 6. Дворянский С.А., Емельянова Д.И., Яговкина Н.В. Климактерический синдром: современное состояние вопроса (обзор литературы). Вятский медицинский вестник. 2017;1(53):7–15.Dvoryanskiy S.A., Emelyanova D.I., Yagovkina N.V. Climacteric syndrome: current status of the issue (literature review). Vyatskiy meditsinskiy vestnik. 2017;1(53):7–15 (in Russ.). 7. Ramírez I., De la Viuda E., Baquedano L. et al. Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemostasia. Maturitas. 2020;137:57–62. DOI: 10.1016/j.maturitas.2020.04.019. 8. Cagnacci A., Bonaccorsi G., Gambacciani M.; board of the Italian Menopause Society. Reflections and recommendations on the COVID-19 pandemic: Should hormone therapy be discontinued? Maturitas. 2020;138:76–77. DOI: 10.1016/j.maturitas.2020.05.022. 9. Gibson C.M., Spyropoulos A.C., Cohen A.T. et al. The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. TH Open. 2017;1(1):e56–e65. DOI: 10.1055/s-0037-1603929. 10. Takahashi T.A., Johnson K.M. Menopause. Med Clin North Am. 2015;99(3):521–534. DOI: 10.1016/j.mcna.2015.01.006. 11. Navas-Otero A., Calvache-Mateo A., Martín-Núñez J. et al. Characteristics of Frailty in Perimenopausal Women with Long COVID-19. Healthcare (Basel). 2023;11(10):1468. DOI: 10.3390/healthcare11101468. 12. Fernández-de-Las-Peñas C., Martín-Guerrero J.D., Pellicer-Valero Ó.J. et al. Female Sex Is a Risk Factor Associated with Long-Term Post-COVID Related-Symptoms but Not with COVID-19 Symptoms: The LONG-COVID-EXP-CM Multicenter Study. J Clin Med. 2022;11(2):413. DOI: 10.3390/jcm11020413. 13. Li K., Chen G., Hou H. et al. Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age. Reprod Biomed Online. 2021;42(1):260–267. DOI: 10.1016/j.rbmo.2020.09.020. 14. Madendag I.C., Madendag Y., Ozdemir A.T. COVID-19 disease does not cause ovarian injury in women of reproductive age: an observational before-and-after COVID-19 study. Reprod Biomed Online. 2022;45(1):153–158. DOI: 10.1016/j.rbmo.2022.03.002. 15. Heneka M.T., Golenbock D., Latz E. et al. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther. 2020;12(1):69. DOI: 10.1186/s13195-020-00640-3. 16. Muccioli L., Pensato U., Cani I. et al. COVID-19-Associated Encephalopathy and Cytokine-Mediated Neuroinflammation. Ann Neurol. 2020;88(4):860–861. DOI: 10.1002/ana.25855. 17. Pertyńska-Marczewska M., Pertyński T. Premenopausal and postmenopausal women during the COVID-19 pandemic. Prz Menopauzalny. 2022;21(3):200–206. DOI: 10.5114/pm.2022.118695. 18. Stewart S., Newson L., Briggs T.A. et al. Long COVID risk — a signal to address sex hormones and women's health. Lancet Reg Health Eur. 2021;11:100242. DOI: 10.1016/j.lanepe.2021.100242. 19. Cagnacci A., Bonaccorsi G., Gambacciani M.; board of the Italian Menopause Society. Reflections and recommendations on the COVID-19 pandemic: Should hormone therapy be discontinued? Maturitas. 2020;138:76–77. DOI: 10.1016/j.maturitas.2020.05.022. 20. Ramírez I., De la Viuda E., Baquedano L. et al. The thromboembolic risk in covid-19 women under hormonal treatment group. Maturitas. 2020;138:78–79. DOI: 10.1016/j.maturitas.2020.05.021.

This work is licensed under a Creative Commons «Attribution» 4.0 License.

Read the article in PDF in Russian

Внутриутробная хирургическая коррекция у...

1689

Correction of hormonal status, reproduct...

1545

All articles